Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1881 3
1882 2
1883 1
1884 3
1885 2
1887 2
1888 2
1889 1
1890 1
1922 1
1935 1
1947 2
1951 1
1952 1
1953 1
1954 2
1955 1
1956 2
1957 4
1958 2
1959 3
1960 1
1961 1
1962 1
1963 2
1964 2
1965 6
1966 5
1967 3
1968 4
1969 5
1970 3
1973 5
1974 1
1976 1
1978 4
1979 1
1981 1
1983 4
1984 4
1985 2
1986 3
1988 1
1989 2
1990 2
1991 2
1992 4
1993 1
1994 1
1995 2
1996 3
1997 12
1998 3
1999 1
2000 4
2001 5
2002 1
2003 1
2006 3
2007 2
2008 2
2009 5
2010 4
2011 7
2012 5
2013 2
2014 6
2015 7
2016 10
2017 10
2018 9
2019 19
2020 15
2021 23
2022 14
2023 8
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Results by year

Filters applied: . Clear all
Page 1
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group. Middleton PG, et al. N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31. N Engl J Med. 2019. PMID: 31697873 Free PMC article. Clinical Trial.
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group. Heijerman HGM, et al. Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31. Lancet. 2019. PMID: 31679946 Free PMC article. Clinical Trial.
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group. Wainwright CE, et al. N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17. N Engl J Med. 2015. PMID: 25981758 Free PMC article. Clinical Trial.
Constipation-Silicea.
Nash EB. Nash EB. Homoeopath Physician. 1881 Feb;1(2):69-71. Homoeopath Physician. 1881. PMID: 37134355 Free PMC article. No abstract available.
Stump Appendicitis.
Essenmacher AC, Nash E, Walker SK, Pitcher GJ, Buresh CT, Sato TS. Essenmacher AC, et al. Among authors: nash e. Clin Pract Cases Emerg Med. 2018 May 18;2(3):211-214. doi: 10.5811/cpcem.2018.3.37730. eCollection 2018 Aug. Clin Pract Cases Emerg Med. 2018. PMID: 30083635 Free PMC article.
Levetiracetam.
Nash EM, Sangha KS. Nash EM, et al. Am J Health Syst Pharm. 2001 Jul 1;58(13):1195-9. doi: 10.1093/ajhp/58.13.1195. Am J Health Syst Pharm. 2001. PMID: 11449876 Review.
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA; VX18-445-109 study group. Sutharsan S, et al. Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20. Lancet Respir Med. 2022. PMID: 34942085 Clinical Trial.
Infectious Disease in Contact Sports.
Peterson AR, Nash E, Anderson BJ. Peterson AR, et al. Among authors: nash e. Sports Health. 2019 Jan/Feb;11(1):47-58. doi: 10.1177/1941738118789954. Epub 2018 Aug 14. Sports Health. 2019. PMID: 30106670 Free PMC article. Review.
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
Uluer AZ, MacGregor G, Azevedo P, Indihar V, Keating C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Rubenstein RC, Taylor-Cousar JL, Tullis E, Yonker LM, Chu C, Lam AP, Nair N, Sosnay PR, Tian S, Van Goor F, Viswanathan L, Waltz D, Wang LT, Xi Y, Billings J, Horsley A; VX18-121-101; VX18-561-101 Study Groups. Uluer AZ, et al. Lancet Respir Med. 2023 Jun;11(6):550-562. doi: 10.1016/S2213-2600(22)00504-5. Epub 2023 Feb 23. Lancet Respir Med. 2023. PMID: 36842446 Free article. Clinical Trial.
277 results